Redx, the drug development company, has today announced that Phil Tottey, Chief Financial Officer, will be stepping down from the Board and leaving the Company on 30 September 2016 to pursue new opportunities. The company has said that Andrew Booth, who is currently Financial Controller, will act as Interim Finance Director pending a permanent appointment.
In the meantime, the press release office said that the Board is welcoming Karl Hård to the Executive Management Team as Head of Investor Relations and Corporate Communications. Karl has spent almost 20 years at AstraZeneca PLC.
Over the last nine years, he held senior roles within Investor Relations, latterly as Vice President. Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.
Neil Murray, Chief Executive of Redx, commented:
“On behalf of the Board, I would like to thank Phil for his significant contribution to Redx and particularly for his work during the Company’s IPO. We wish him well in his future endeavours.